FDA grants breakthrough device designation to GuardantOMNI test usedfor plasma-based tumor mutational burden analysis ...
SOLAR-1 evaluated BYL719 plus fulvestrant vs. fulvestrant alone in HR+/HER2- advanced breast cancer patients ...
BOSTON, Sept. 01, 2017 (GLOBE NEWSWIRE) -- ZIOPHARM Oncology, Inc. (Nasdaq:ZIOP), a biopharmaceutical company focused ...
